Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme
Language English Country Greece Media print
Document type Journal Article, Review
PubMed
28011470
DOI
10.21873/anticanres.11285
PII: 37/1/21
Knihovny.cz E-resources
- Keywords
- CTLA4 inhibition, GBM, Glioblastoma multiforme, PD1 inhibition, clinical trials, immune checkpoint inhibitors, immunotherapy, personalized medicine, review, targeted therapy,
- MeSH
- Molecular Targeted Therapy adverse effects trends MeSH
- Glioblastoma genetics immunology metabolism therapy MeSH
- Immunotherapy adverse effects trends MeSH
- Angiogenesis Inhibitors therapeutic use MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Humans MeSH
- Antibodies, Monoclonal adverse effects therapeutic use MeSH
- Biomarkers, Tumor antagonists & inhibitors genetics immunology metabolism MeSH
- Tumor Microenvironment MeSH
- Brain Neoplasms genetics immunology metabolism therapy MeSH
- Antineoplastic Agents adverse effects therapeutic use MeSH
- Signal Transduction drug effects MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Angiogenesis Inhibitors MeSH
- Protein Kinase Inhibitors MeSH
- Antibodies, Monoclonal MeSH
- Biomarkers, Tumor MeSH
- Antineoplastic Agents MeSH
Glioblastoma multiforme (GBM) represents the most malignant primary brain tumor in adults with generally dismal prognosis, early clinical deterioration and high mortality. GBM is extremely invasive, characterized by intense and aberrant vascularization and high resistance to multimodal treatment. Standard therapy (surgery, radiotherapy and chemotherapy with temozolomide) has very limited effectiveness, with median overall survival of patients no longer than 15 months. Progress in genetics and epigenetics of GBM over the past decade has revealed various aberrations in cellular signaling pathways, the tumor microenvironment, and pathological angiogenesis. A number of targeted anticancer drugs, such as small-molecule kinase inhibitors and monoclonal antibodies, have been evaluated in clinical trials with newly-diagnosed, as well as recurrent GBM. Unfortunately, to date, only a single anti-angiogenic agent, bevacizumab, has been approved for the treatment of recurrent GBM in the USA and Canada. The novel possibilities of cancer immunotherapy, especially immune checkpoint inhibitors, are being evaluated in clinical trials of patients with GBM. The most recent clinical experiences with targeted therapy as well as immunotherapy of GBM are given in this review. The relative lack of success of some of these approaches recently revealed in well-designed randomized clinical trials is also discussed.
References provided by Crossref.org
